Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.argenx signs agreement to buy Forte Biosciences for $2.2bn
Approved by both companies’ boards of directors, the transaction is expected to close in the third quarter of 2026, contingent upon standard closing conditions. The main asset involved
Approved by both companies’ boards of directors, the transaction is expected to close in the third quarter of 2026, contingent upon standard closing conditions. The main asset involved
This integrated service platform is designed to meet growing demand as computational methods increasingly generate large numbers of candidate antibody sequences in a single design cycle. However, the
This combination aims to provide an additional non-opioid pain relief option without the need for prescriptions. The approval introduces a new choice for individuals seeking relief from persistent
The new investment increases BeOne Medicines’ total spend on US manufacturing facilities to exceed $1bn. This expansion will increase the company’s production capacity for its cancer medicines and
Lu AH69593 is an oral, small-molecule agonist of the orexin 2 receptor (OX2R). The compound is currently being studied in a Phase Ib clinical trial focused on patients
As part of the collaboration, Evogene will use its ChemPass AI platform, a computational chemistry system aimed at generative molecular design, to create, optimise, and rank prospective small-molecule
The gene therapy is under investigation in adults living with BAG3 DCM, a genetic condition that leads to progressive heart failure and reduced survival despite existing treatments. AFTX-201
The announcement follows a positive recommendation issued in April 2026 by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). This regulatory action permits
PPL-001 is a gene-corrected haematopoietic stem and progenitor cell (HSPC) therapy. Under the collaboration, Cellares will adapt the PPL-001 manufacturing process for its Cell Shuttle platform, and support
An autologous anti-cluster of differentiation 20/B-cell maturation antigen (CD20/BCMA) chimeric antigen receptor T-cell (CAR-T) therapy, C-CAR168 aims to treat refractory systemic lupus erythematosus (SLE), with or without lupus